Cytotoxic Constituents from Leaves of Aglaia elliptifolia

Shang-Kwei Wang,[†] Yu-Jyh Cheng,[‡] and Chang-Yih Duh^{*,‡}

Department of Microbiology, Kaohsiung Medical University, Kaohsiung 807, Taiwan, and Department of Marine Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan

Received July 7, 2000

Three new cytotoxic compounds, rocagloic acid (1), elliptifoline (2), and elliptinol (3) were isolated from the leaves of *Aglaia elliptifolia*. The structures of compounds 1-3 were determined by spectral (NMR, MS) and chemical analysis.

In search for bioactive substances from natural sources, leaves of the Formasan plant *Aglaia elliptifolia* Merr. (Meliaceae) were studied. The methanol extract showed significant cytotoxicity in A549 (human lung adenocarcinoma), HT-29 (human colon aenocarcinoma), KB (human oral epidermoid carcinoma), HL-60 (human leukemia), and P-388 (mouse lymphocytic leukemia) cell cultures as determined by standard procedures.^{1,2} Bioassay-guided fractionations resulted in the isolation of two new cytotoxic racaglamide derivatives, rocagloic acid (1) and elliptifoline (2); three diamides, elliptinol (3) (new compound), dehydroodorin (4),³ and piriferine;⁴ a damarane triterpene, foveolin B;⁵ and a flavonoid, 3-hydroxy-5,7,4'-trimethoxy-flavone.⁶



Rocagloic acid (1) was shown to possess a molecular formula of $C_{27}H_{26}O_8$ by HRFABMS. Its IR spectrum showed hydroxyl (3500 cm⁻¹) and carbonyl (1665 cm⁻¹) absorption. The ¹H NMR spectrum of **1** showed three methoxy groups at δ 3.65, 3.80, 3.81. In addition, signals of three aromatic rings similar to those of methyl rocaglate were observed,⁷ that is, two meta-coupled aromatic protons at δ 6.09 and 6.25 (2d, J = 1.9 Hz), the characteristic AA'BB' system of a *p*-disubstituted benzene ring at δ 6.61 and 7.09, and the signals of a monosubstituted benzene ring (5H, m, δ 7.01–7.08). The spectrum further exhibited signals at δ 4.89 (d, J = 5.6 Hz), 3.79 (dd, J = 14.1, 5.6 Hz) and 4.25 (d, J =

14.1 Hz) typical of H-1, H-2, and H-3 of methyl rocaglate.⁷ The ¹³C NMR spectrum of **1** was also similar to that of methyl rocaglate, showing the signals of a tetrasubstituted, a disubstituted, and a monosubstituted bezene ring; a carboxylic C=O at δ 172.8; and two characteristic quaternary carbons C-3a and C-8b at δ 101.9 and 93.6. Thus, owing to the elemental composition and the lack of a methyl group, the structure of **1** was assigned as shown. Saponification of methyl rocaglate⁸ and conversion to **1** further confirmed the structure.

Elliptifoline (2) was shown to possess a molecular formula of C₃₆H₄₀N₂O₈ by HRFABMS. Its IR spectrum showed hydroxyl absorption at 3650 cm⁻¹ and carbonyl absorptions at 1635 and 1620 cm⁻¹, corresponding to amide functions. The ¹H and ¹³C NMR spectra of 2 indicated three methoxyl groups and three benzene rings similar to 1. In addition, signals of a tigloyl amide and a 2-aminopyrrolidine ring reminiscent of those reported for dehydroodorin were observed, suggesting that part of the dehydroodorin (4) structure could be linked through an amide function to an acid moiety of the rocagloic acid instead of the OH group. The ¹H NMR spectrum of **1** also showed three signals of methine protons at δ 4.45, 4.15, and 4.80, which could correspond to the 1, 2, 3 position in rocagloic acid. However, the coupling patterns of the three protons differed from those of rocagloic acid. The proton at δ 4.80 appeared as a sharp singlet, while the two others were coupled (9.2 Hz), which is compatible with 3α , 4β -configuration.⁹ Signals of quaternary carbons C-3a and C-8b with typical chemical shifts present at δ 101.9 and 93.6 were lacking and replaced by two quaternary carbon signals at δ 88.9 and 81.9. These ¹H and ¹³C NMR data suggested that elliptifoline has the formula depicted in 2, with a pyran ring in place of the furan of rocagloic acid.⁹ In the HMBC experiment, the cross-peaks H-10/C-2, C-3, C-4, C-5a; H-4/C-3, C-5, C-5a, C-10, C-11, C-1"; and H-3/C-2, C-4, C-10 supported the relative positions 2, 3, 4, 5, and 10, whereas the correlations from H-3 to C-1",-2",-6" and H-4 to C-11 indicated the connectivities of C-3 to the monosubstituted benzene ring and C-4 to C-11, respectively. NOESY relationships H-4/H-2",-6", H-3/H2"-6", H-4/ OH-10 further confirmed these assignments and established the relative configuration at C-2, C-3, C-4, C-5, and C-10 as depicted in formula 2. The ¹³C NMR chemical shift of C-10 (δ ca. 80)⁹ also confirmed the relative configuration at this carbon. In addition, the NOESY cross-peak H-4/H-13 established that the relative configuration at C-13 is S, as depicted in 2.

Compound **3** had molecular formula $C_{18}H_{24}O_3N_2$ as determined by HREIMS. Presence of a cinnamoyl moiety was indicated by the appearance of mass peaks at m/z 131

10.1021/np000341q CCC: \$20.00 © 2001 American Chemical Society and American Society of Pharmacognosy Published on Web 11/23/2000

^{*} To whom correspondence should be addressed. Tel.: 886-7-525-2000, ext. 5036. Fax: 886-7-525-5020.

[†] Kaosiung Medical University

[‡] National Sun Yat-sen University.

(PhCH=CHCO) and 103 (PhCH=CH) and by IR bands at 1665, 1620, and 1550 cm⁻¹, and was substantiated by the presence in the ¹H NMR spectrum of characteristic low-field signals at δ 7.57 (1H, d, J = 15.6 Hz), 6.39 (1H, d, J = 15.6 Hz), and 7.35 (3H, m), 7.47 (2H, m). The presence of a tigloyl moiety was indicated by ¹³C NMR signals at δ 169.9 s, 131.4 s, 132.2 d, 14.1 q, and 12.3 q. Comparing the rest of ¹³C NMR signals (δ 62.4 d, 28.7 t, 30.6 t, and 58.8 t) and the molecular formula of **3** with those of **4**³ suggested that elliptinol had the structure depicted in formula **3**, with a 1-hydroxy-4-aminobuta-4-yl moiety in place of the pyrrolidin-2-yl moiety in **4**. This structure was further confirmed by COSY and HMBC experiments.

Experimental Section

General Experimental Procedures. Melting points were determined using a Yanagimoto micromelting point apparatus and are reported uncorrected. Optical rotations were determined on a JASCO DIP-181 polarimeter. IR spectra were recorded on a Hitachi 26-30 spectrophotometer. ¹H and ¹³C NMR spectra were recorded with a Bruker AMX 400 NMR spectrometer at 400 and 100.6 MHz, respectively, in CDCl₃ using TMS as internal standard. EIMS were obtained with a JEOL JMS-SX/SX 102A mass spectrometer at 70 eV. Si gel 60 (Merck, 230–400 mesh) was used for column chromatography; precoated Si gel plates (Merck, Kieselgel 60 F₂₅₄, 0.25 mm) were used for TLC analysis.

Plant Material. The leaves of *A. elliptifolia* were collected in Pintong County, Taiwan, in February 1990. A voucher specimen (PT-012) is deposited in the Department of Marine Resources, National Sun Yat-sen University, Taiwan.

Extraction and Isolation. Dry ground leaves (10.2 kg) of A. elliptifolia were extracted with MeOH. After removal of solvent in vacuo, the residue (760 g) was partitioned between CHCl₃ and H₂O. The CHCl₃-soluble extract exhibited significant cytotoxicity against several cell lines tested. The CHCl₃soluble extract (630 g) was chromatographed over Si gel 60 using CHCl₃ and MeOH-CHCl₃ mixtures of increasing polarity. The fraction (ED₅₀ 0.06 μ g/mL, 20 g) that was eluted with MeOH-CHCl₃ (1:49) was subjected to repeated Si gel column chromatography (CC) and Sephadex LH-20 CC yielding elliptifoline (2) (72 mg) (a) silica CC n-hexane-EtOAc (1:1) (b) silica CC n-hexane-EtOAc-Me₂CO-CHCl₃ (2:1:1:1), and (c) LH-20 CC *n*-hexane-CH₂Cl₂ (1:1). The fraction (ED₅₀ 0.5 μ g/mL, 12 g) that was eluted with MeOH-CHCl₃ (1:9) was subjected to repeated Si gel CC and Sephadex LH-20 CC yielding elliptinol (3) (5 mg) (a) silica CC n-hexane-EtOAc (1:4), (b) silica CC n-hexane-CHCl3-Me2CO-MeOH (8:4:3:1), and (c) LH-20 CC n-hexane-CH₂Cl₂ (1:1); rocagloic acid (1) (36 mg) (a) silica CC CHCl₃-Me₂CO (2:3) and (b) LH-20 CC Me₂CO-CH₂Cl₂ (2:3); fovelin B (20 mg) (a) silica CC n-hexane-Me₂CO (2:3) and (b) LH-20 CC *n*-hexane-CH₂Cl₂ (1:1). The fraction $(ED_{50}~5.6~\mu g/mL,~15~g)$ that was eluted with $CHCl_3$ was subjected to repeated Si gel CC and Sephadex LH-20 CC yielding 3-hydroxy-5,7,4'-trimethoxyflavone (25 mg) (a) silica CC n-hexane-EtOAc (1:1) and (b) LH-20 CC n-hexane-CH₂Cl₂ (1:1); dehydroodorin (106 mg) (a) n-hexane-EtOAc (1:1). The fraction (ED_{50} 6.7 μ g/mL, 10 g) that was eluted with MeOH-CHCl₃ (1:19) was subjected to Sephadex LH-20 CC [n-hexaneacetone (1:1)] yielding piriferine (15 mg).

Rocagloic acid (1): white powder; mp 145–146°; $[\alpha]^{22}_{\rm D}$ –47.6° (*c* 0.02, CHCl₃); UV (MeOH) $\lambda_{\rm max}$ (log ϵ) 273 (3.36) nm; IR (KBr) $\nu_{\rm max}$ 3500, 1665, 1600, 1510 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 3.65 (3H, s, OMe-4'), 3.79 (1H, dd, J = 14.1, 5.6 Hz, H-2), 3.80 (3H, s, OMe-8), 3.81 (3H, s, OMe-6), 4.25 (1H, d, J = 14.1 Hz, H-3), 4.89 (1H, d, J = 5.6 Hz, H-1), 6.09 (1H, d, J = 1.9 Hz, H-7), 6.25 (1H, d, J = 1.9 Hz, H-5), 6.61 (2H, d, J = 9.0 Hz, H-3',-5'), 7.01 (2H, m, H-2'',-6''), 7.05 (2H, m, H-3'', -5''), 7.08 (1H, m, H-4''), 7.09 (2H, d, J = 9 Hz, H-2',-6'); ¹³C NMR (CDCl₃, 100 MHz) δ 51.7 (d, C-2), 55.2 (s, OMe-4'), 55.7 (s, OMe-6), 55.8 (s, OMe-8), 56.3 (d, C-3), 79.0 (d, C-1), 89.3

Table 1. Cytotoxicitiy^{*a*} of 1-3 (n = 8)

	-	-			
com- pound	ED ₅₀ (µg/mL) in indicated cell line				
	A549	HL-60	HT-29	KB	P-388
1	0.00074	0.00084	0.00084	0.0023	0.0012
2	18.9	>50	>50	>50	3.41
3	>50	32.1	>50	>50	3.62

 a For significant activity of pure compounds, an ED_{50} of $\leq 4.0~\mu g/mL$ is required.^1

(d, C-5), 92.5 (d, C-7), 93.6 (s, C-8b), 101.9 (s, C-3a), 107.2 (s, C-8a), 112.7 (d, C-3',-5'), 126.6 (s, C-1'), 127.0 (d, C-4''), 128.0 (d, C-3'',-5''), 128.3 (d, C-2'',-6''), 129.1 (d, C-2',-6'), 136.4 (s, C-1''), 157.4 (s, C-8), 158.8 (s, C-4'), 161.1 (s, C-4a), 164.1 (s, C-6), 172.8 (s); FABMS m/z [MH]⁺ 479 (1), 461 (15), 443 (13), 415 (20), 390 (20), 313 (92), 300 (100); HRFABMS m/z 479.1703 (calcd for C₂₇H₂₇O₈ 479.1698).

Elliptifoline (2): white powder; mp $184-185^{\circ}$; $[\alpha]^{22}_{D}$ -88.9° (*c* 0.6, CHCl₃); UV (MeOH) λ_{max} (log ϵ) 273 (3.36) nm; IR (KBr) ν_{max} 3650, 3440, 1635, 1620, 1598 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.47 (3H, s, H-22), 1.63 (3H, d, J = 7.0 Hz, H-21), 1.84 (2H, m, H-15), 2.02 (2H, m, H-14), 3.21, 3.58 (1H each, m, H-16), 3.66 (3H, s, OMe-4'), 3.71 (3H, m, OMe-8), 3.80 (3H, m, OMe-6), 4.15 (1H, d, J = 9.2 Hz, H-4), 4.45 (1H, d, J=9.2 Hz, H-3), 4.62 (1H, s, OH-10), 4.80 (1H, s, H-10), 5.57 (1H, d, J = 7.9 Hz, NH-17), 5.88 (1H, s, OH-5), 6.02 (1H, m, H-20), 6.06 (1H, m, H-7), 6.09 (1H, m, H-9), 6.60 (2H, m, H-3',-5'), 6.63 (1H, m, H-13), 6.89 (2H, m, H-3",-5"), 6.91 (1H, m, H-4"), 7.11 (2H, m, H-2",-6"), 7.41 (2H, m, H-2',-6'); ¹³C NMR (CDCl₃, 100 MHz) δ 12.0 (q, C-22), 13.9 (q, C-21), 21.4 (t, C-15), 34.5 (t, C-14), 46.1 (t, C-16), 55.0 (s, OMe-4'), 55.2 (s, OMe-8), 56.0 (s, OMe-6), 57.1 (d, C-3), 62.3 (d, C-4), 63.7 (d, C-13), 79.7 (d, C-10), 81.9 (s, C-5), 88.9 (s, C-2), 91.9 (d, C-7), 94.2 (d, C-9), 105.4 (s, C-5a), 112.6 (d, C-3',-5'), 125.6 (d, C-4''), 127.7 (d, C-3",-5"), 130.2 (d, C-2",-6"), 130.4 (d, C-2',-6'), 130.7 (s, C-19), 131.8 (d, C-20), 141.8 (s, C-1"), 153.7 (s, C-1a), 158.1 (s, C-6), 158.4 (s, C-4'), 161.0 (s, C-8), 167.9 (s, C-18), 169.9 (s, C-11); FABMS m/z [MH]⁺ 629 (6), 530 (1), 461 (1), 376 (17), 313 (84), 181 (53), 70 (100); HRFABMS m/z 629.2863 (calcd for $C_{36}H_{41}N_2O_8$ 629.2863).

Elliptinol (3): white powder; mp $162-163^{\circ}$; [α]²²_D +38.6° (c 0.05, CHCl₃); UV (MeOH) λ_{max} (log ϵ) 283 (4.66) nm; IR (KBr) ν_{max} 3650, 1665, 1620, 1550 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.61 (2H, m, H-3'), 1.75 (3H, d, J = 6.9 Hz, H-4), 1.83 (3H, s, H-5), 2.15 (2H, m, H-4'), 3.71 (1H, t, J = 6.0 Hz, H-2'), 5.41 (1H, m, H-5'), 6.39 (1H, d, J = 15.6 Hz, H-2''), 6.49 (1H, q, J = 6.9 Hz, H-3), 7.35 (3H, m, H-5'',-6'',-7''); 7.47 (2H, m, H-5'', -9''), 7.57 (1H, H-3''); ¹³C NMR (CDCl₃, 100 MHz) δ 12.3 (q, C-5), 14.1 (q, C-4), 28.7 (t, C-3'), 30.6 (t, C-4'), 58.8 (t, C-5''), 62.4 (d, C-2'), 120.7 (d, C-2''), 127.9 (d, C-5'',-9''), 128.9 (d, C-6'', -8''), 129.9 (d, C-7''), 131.4 (s, C-2), 132.2 (d, C-3), 134.7 (s, C-4''), 141.7 (d, C-3''), 166.3 (s, C-1''), 169.6 (s, C-1); EIMS m/z [M]⁺ 316 (0.5), 258 (8), 257 (47), 217 (5), 189 (5), 146 (17), 131 (100), 103 (39); HREIMS m/z 316.1787 (calcd for C₁₈H₂₄N₂O₃ 316.1788).

Saponification of Methyl Rocaglate and Conversion to 1. Methyl rocaglate (30 mg) was dissolved in 0.5% KOH– aqueous MeOH [MeOH–H₂O (1:2)] and refluxed at 65 °C for 5 h. The reaction mixture was neutralized with diluted HCl and diluted with saturated NaCl. The solution was then extracted with Et₂O to get 20 mg of 1 [crystallized from Me₂CO–MeOH (1:1)].

Cytotoxicity Testing. KB and P-388 cells were supplied by Prof. J. M. Pezzuto, University of Illinois at Chicago. The A549, HL-60, and HT-29 cells were purchased from the American Type Culture Collection. Cytotoxicity asssays were carried out according to the procedure described previously.¹⁰ Cytotoxicity of 1-3 is shown in Table 1.

Acknowledgment. We thank Prof. J. M. Pezzuto, Program for Collaborative Research in Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, for the provision of KB and P-388 cell lines, as well as Dr. F.-J. Ho in the Department of Forest Adminstration of Taiwan for the identification of the plant materials. This work was supported by grants from the National Sciences Council of Taiwan awarded to C.-Y.D.

References and Notes

- Geran, R. I.; Greenberg, N. H.; MacDonald, M. M.; A. M. Schumacher, A. M.; Abbott, B. J. *Cancer Chemother. Rep.* **1972**, *3*, 1–91.
 Hou, R.-S.; Duh, C.-Y.; Chiang, M. Y.; Lin, C.-N. J. Nat. Prod. **1995**, 500 (2010)
- (2) Thu, R.-S., Dun, C.-T., Chiang, M. T., Ehr, C.-W. J. Nat. Prod. 1959, 58, 1126–1130.
 (3) Duh, C.-Y.; Wang, S.-K.; Hou, R.-S.; Wu, Y.-C.; Wang, Y.; Cheng, M.-C.; Chang, T. T. *Phytochemistry* 1993, 857–858.
 (4) Saifah, E.; Jongbunprasert, V. J. Nat. Prod. 1988, 51, 80–82.

- (5) Roux, D.; Martin, M.-T.; Adeline, M.-T.; Sevenet, T.; Hadi, A. H. A.;
- (6) Roux, D., Martin, M. T., Auemie, M. T., Sevenet, T., Hadi, A. H. A., Pais, M. *Phytochemistry* **1998**, *49*, 1745–1748.
 (6) Dong, H.; Gou, Y.-L.; Cao, S.-G.; Chen, S.-X.; Sim, K.-Y.; Goh, S.-H.; Kini, R. M. *Phytochemistry* **1999**, *50*, 889–902.
- (7) Cui, B.; Chai, H.; Santisuk, T.; Reutrakul, V.; Fansworth, N. R.; Cordell, G. A.; Pezzuto, J. M.; Kinghorn, A. D. Tetrahedron 1997, 53, 17625-17632.
- (8) Isolated from the stem barks of Aglaia formosana.
- (9) Nugroho, B. W.; Edrada, R. A.; Güssrengen, V.; Wary, V.; Witte, L.; (b) Pugran, D. W. Darada, R. B. Gasslengen, V. Wary, V. Wiley, L. Proksch, P. *Phytochemistry* **1997**, *44*, 1455–1461.
 (10) Duh, C.-Y.; Wang, S.-K.; Weng, Y.-L.; Chiang, M. Y.; and Dai, C.-F.
- J. Nat. Prod. 1999, 62, 1518-1521.

NP000341Q